Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de desafio de dose única controlado por placebo de gaboxadol em homens adultos com síndrome do X frágil (FXS)

8 de setembro de 2026 atualizado por: Craig Erickson

This is a single dose, placebo-controlled study. Male subjects aged 18 to 40 years (inclusive) with a diagnosis of FXS. Eligible subjects may enroll in this study comprised of two in home and two in clinic visits each 14 days apart, for a total of four visits. Subjects will be given single dose gaboxadol (10 mg) or matched placebo at each of these visits to take orally. Thus, all enrolled subjects will receive placebo at home and in clinic and receive gaboxadol at home and in clinic in a blinded fashion.

Visão geral do estudo

Status

Concluído

Tipo de estudo

Intervencional

Inscrição (Real)

10

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229
        • Cincinnati Children's Hospital Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 40 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria:

  1. Subject consents to participate, or if they are not their own legal guardian, offers assent supported by legally authorized representative consent
  2. Subject is willing and able to comply with the study procedures as specified in the protocol and to comply with the study drug administration. Caregiver also commits to the study requirements prior to any study-related procedures
  3. Subject and caregiver are both able to understand the spoken national language clearly and caregiver can read and write to complete study assessments
  4. Males age 18 to 40 years (inclusive)
  5. Has FXS with molecular genetic confirmation of the full FMR1 mutation (>200 cysteine-guanine-guanine [CGG] repeats). May have been confirmed historically or at Screening
  6. Is in general good health as deemed by the Investigator, determined by physical examination, medical history, and laboratory tests
  7. If receiving serotonin-selective reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or serotonin antagonist and reuptake inhibitor (SARI), is on a stable, well-tolerated dose for the previous 3 months with no further changes anticipated
  8. Is not sexually active or can confirm at least one form of contraceptive

Exclusion Criteria:

  1. Any chronic major medical comorbid condition deemed by the Investigator as presenting added risk to the subject, including but not limited to, refractory hypertension, kidney disease, or liver disease
  2. Diagnosed with diabetes (Type 1 or II) or receiving any anti-diabetic medication
  3. Unstable seizure disorder, defined by any seizure within 6 months prior to baseline visit and/or a change in any anti-convulsant drug dosing in the 60 days prior to study consent
  4. Changes in psychotropic or anti-convulsant (where taken for reasons other than seizure control) drug treatment within 30 days prior to Screening
  5. Significant changes in any educational, behavioral, and/or dietary interventions the month prior to Screening
  6. Planned initiation of new, or modification of ongoing, interventions during the study
  7. Unable or unwilling to take oral medication (whole capsule, despite assistance with a spoonful of applesauce, yoghurt, or equivalent liquid food)
  8. Consumption of liver enzyme inducers or inhibitors including and not limited to foods, medicines, herbal remedies and supplements three days prior to any Visit. Foods or beverages containing CYP3A4/5 inhibitors (e.g., grapefruit, pomegranate, pomelo, and star fruit) should be avoided before taking study medication and for up to 1 hour post dose throughout the study
  9. Has abnormal baseline laboratory assessments including, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin >1.5 × the upper limit of normal (ULN), serum creatinine >1.5 x ULN or other clinically relevant laboratory abnormality
  10. Has a clinically significant heart rate or blood pressure (BP) at Screening as judged by the Investigator
  11. Has received an investigational drug in any prior clinical study within 30 days or 5 half-lives (whichever is longer) prior to Screening

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Placebo in lab, Gaboxadol in home, Gaboxadol in lab, Placebo in home

Individuals in this condition received Placebo in lab, Gaboxadol in home, Gaboxadol in lab, then Placebo in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Experimental: Gaboxadol in lab, Gaboxadol in home, Placebo in lab, Placebo in home

Individuals in this condition received Gaboxadol in lab, Gaboxadol in home, Placebo in lab, then Placebo in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Experimental: Placebo in lab, Placebo in home, Gaboxadol in lab, Gaboxadol in home

Individuals in this condition received Placebo in lab, Placebo in home, Gaboxadol in lab, then Gaboxadol in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Experimental: Gaboxadol in lab, Placebo in home, Placebo in lab, Gaboxadol in home

Individuals in this condition received Gaboxadol in lab, Placebo in home, Placebo in lab, then Gaboxadol in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Target Engagement of Gaboxadol Treatment on EEG Power
Prazo: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in EEG recordings with gaboxadol treatment (assessed at pre-dose, 60 minutes post-dose, average response across home and lab reported). compared with pre-dose on resting theta, alpha and gamma band absolute power. Absolute power measures reflect the median power averaged across 129 electrodes in μV²/Hz. Means are presented using the average of home and lab values.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
Target Engagement of Gaboxadol Treatment on Auditory Chirp
Prazo: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in EEG recordings with gaboxadol treatment (60-90 minutes post-dose compared with pre-dose on brain response to auditory chirp stimuli), as measured by intertrial phase coherence (ITC). Means are presented using the average of home and lab values.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
To Investigate the Feasibility of Home Research Visits and Procedures in Adult Males With FXS
Prazo: Pre-dose, 60 minutes post-dose

Quality and test-retest reliability of assessments performed at home compared with the hospital setting. This includes blood testing for Fragile X messenger ribonucleoprotein (FMRP: range of 0-40 picomolar) and eye-tracking of eye gaze to eye regions when viewing faces (range of value from 0 percent to 100 percent; higher values are associated with a neurotypical phenotype).

Pre-dose, 60 minutes post-dose
To Investigate the Feasibility of High Density EEG Recording at Home in Adult Males With FXS
Prazo: Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42

This endpoint examined the reliability of pre-dose resting-state EEG absolute power estimates between in-lab and in-home assessments using intraclass correlation (ICC). ICCs were calculated separately for 129 electrodes using absolute power estimates (μV²/Hz). The reported ICC represents the mean ICC across electrodes, with the standard deviation reflecting variability in ICC values across electrodes. whole-head, pre-dose resting state EEG power estimates from data collected in-lab vs in-home using intraclass correlation (ICC).

Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42
To Potentially Explore the Pharmacokinetics of Gaboxadol Treatment in Single-dose Trial Design
Prazo: Sixty minutes post-dose on 4 study visits, up to day 42

PK profile (the level of gaboxadol in human plasma) will be obtained at 60 +/- 10 minutes post-dose only).

Sixty minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments
Prazo: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in cognitive and neuropsychological assessment measures with gaboxadol treatment (RBANS List Learning). During the RBANS List Learning subtests, participants listen to a list of 10 words and repeat back as many as they can remember four times, for a maximum score of 40. Change scores were calculated by subtracting pre-dose words remembered from post-dose words remembered, with positive scores meaning an improvement in memory.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Eye Tracking Assessments
Prazo: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Change in eye tracking outcomes (60-90 minutes post-dose compared to pre-dose on percent viewing of social versus geometric scene

Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Clinician-rated Measures
Prazo: Post-dose on 4 study visits, up to day 42

Score on the Clinical Global Impressions - Improvement (CGI-I) scale, a clinician rating scale with "1" anchored to "very much improved" and "7" anchored to "very much worse."

Post-dose on 4 study visits, up to day 42
To Determine Whether FMRP Levels Predict Treatment Response
Prazo: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Relationship between FMRP (Fragile X messenger ribonucleoprotein) level and degree of change (baseline/screen to post-dose) across measures

Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Cragi A Erickson, MD, Children's Hospital Medical Center, Cincinnati

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

29 de janeiro de 2024

Conclusão Primária (Real)

13 de maio de 2025

Conclusão do estudo (Real)

24 de junho de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

8 de março de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de março de 2024

Primeira postagem (Real)

28 de março de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

30 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

8 de setembro de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever